Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory Study of TLM-017 Ophthalmic Solution for Ocular Graft-Versus-Host Disease
jRCTs031250695Phase 1Recruiting
- Sponsor
- Rohto Pharmaceutical Co., Ltd.
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of recombinant human lactoferrin in ocular graft-versus-host disease (oGVHD) (3 cohorts), sponsored by Rohto Pharmaceutical Co., Ltd. Primary endpoint: Incidence of local ocular adverse events. Started Mar 2026; status: recruiting.
02
Drugs
recombinant human lactoferrin
03
Conditions
ocular graft-versus-host disease (oGVHD)
Beyond the preview
Go deeper on jRCTs031250695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250695.